← Back to headlines
Teva Cuts 2026 Outlook Despite Q1 Beat, Citing Emalex Buyout
Teva Pharmaceutical Industries reported a Q1 earnings beat but subsequently lowered its 2026 financial outlook. The revised forecast is attributed to the company's acquisition of Emalex Biosciences.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
